FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

10 letters match. Newest first.

  1. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  2. Eurofins SF Analytical Laboratories, Inc.

    FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

    High risk
  3. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk
  4. Lico Industries, LLC., d.b.a. American Towelette Company

    FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.

    High risk
  5. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk
  6. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  7. Microbiological Testing & Consulting, LLC

    FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.

    High risk
  8. Diasol, Inc.

    Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.

    High risk
  9. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  10. Integrity Partners Group

    FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.

    High risk